Literature DB >> 16226112

BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.

Scott J Rodig1, Ali Shahsafaei, Betty Li, Charles R Mackay, David M Dorfman.   

Abstract

B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function. In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with autoimmune disease. We sought to determine the normal pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell neoplasms. Most circulating human B cells and a small subset of T cells are BAFF-R-positive. In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone. BAFF-R is also expressed by B cells colonizing the splenic marginal zone. Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma. In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R. All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified. These findings highlight BAFF-R as a marker of both normal and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting normal B-cell maturation and survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226112     DOI: 10.1016/j.humpath.2005.08.005

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  33 in total

1.  Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Authors:  Yorleny Vicioso; Hermann Gram; Rose Beck; Abhishek Asthana; Keman Zhang; Derek P Wong; John Letterio; Reshmi Parameswaran
Journal:  Cancer Immunol Res       Date:  2019-05-28       Impact factor: 11.151

2.  The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.

Authors:  Anthony G Brickner; Anne M Evans; Jeffrey K Mito; Suzanne M Xuereb; Xin Feng; Tetsuya Nishida; Liane Fairfull; Robert E Ferrell; Kenneth A Foon; Donald F Hunt; Jeffrey Shabanowitz; Victor H Engelhard; Stanley R Riddell; Edus H Warren
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

3.  CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Authors:  Hong Qin; Zhenyuan Dong; Xiuli Wang; Wesley A Cheng; Feng Wen; Weili Xue; Han Sun; Miriam Walter; Guowei Wei; D Lynne Smith; Xiuhua Sun; Fan Fei; Jianming Xie; Theano I Panagopoulou; Chun-Wei Chen; Joo Y Song; Ibrahim Aldoss; Clarisse Kayembe; Luisa Sarno; Markus Müschen; Giorgio G Inghirami; Stephen J Forman; Larry W Kwak
Journal:  Sci Transl Med       Date:  2019-09-25       Impact factor: 17.956

4.  B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.

Authors:  E Becerra; I De La Torre; M J Leandro; G Cambridge
Journal:  Clin Exp Immunol       Date:  2017-09-25       Impact factor: 4.330

5.  Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

Authors:  Emily M McWilliams; Christopher R Lucas; Timothy Chen; Bonnie K Harrington; Ronni Wasmuth; Amanda Campbell; Kerry A Rogers; Carolyn M Cheney; Xiaokui Mo; Leslie A Andritsos; Farrukh T Awan; Jennifer Woyach; William E Carson; Jonathan Butchar; Susheela Tridandapani; Erin Hertlein; Carlos E Castro; Natarajan Muthusamy; John C Byrd
Journal:  Blood Adv       Date:  2019-02-12

Review 6.  Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.

Authors:  Stéphanie Haiat; Christian Billard; Claire Quiney; Florence Ajchenbaum-Cymbalista; Jean-Pierre Kolb
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

7.  Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma.

Authors:  Keiko Onda; Kazutoshi Iijima; Yohko U Katagiri; Hajime Okita; Masahiro Saito; Toshiaki Shimizu; Nobutaka Kiyokawa
Journal:  Int J Hematol       Date:  2010-04-29       Impact factor: 2.490

8.  Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.

Authors:  April Chiu; Weifeng Xu; Bing He; Stacey R Dillon; Jane A Gross; Eric Sievers; Xugang Qiao; Paul Santini; Elizabeth Hyjek; Joong-won Lee; Ethel Cesarman; Amy Chadburn; Daniel M Knowles; Andrea Cerutti
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

9.  Elevated serum levels of B-cell activating factor in pediatric renal transplant patients.

Authors:  Anja Lehnhardt; Franziska Dunst; Michael van Husen; Sebastian Loos; Jun Oh; Thomas Eiermann; Martina Koch; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2012-03-28       Impact factor: 3.714

Review 10.  The Role of BAFF System Molecules in Host Response to Pathogens.

Authors:  Jiro Sakai; Mustafa Akkoyunlu
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.